Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCentrica Regulatory News (CNA)

Share Price Information for Centrica (CNA)

Share Price is delayed by 15 minutes
Get Live Data
186.20    1.10 (0.59%)
Bid:
186.15
Ask:
186.25
Spread: 0.10 (0.054%)
Market Cap: £8.43b
CNA Live PriceLast checked at - London Stock Exchange

Intraday Centrica Share Chart

Chair Succession

25 Jul 2024 07:00

RNS Number : 7605X
Centrica PLC
25 July 2024
 

 

 

 

 

25 July 2024

 

Centrica plc

 

Chair Succession

 

Centrica plc ("the Company") today announces that Scott Wheway will step down as Chair of the Company after almost nine years on the Board and five years as Chair and will not seek re-election as a Director. The Board is pleased to announce that, effective 16 December 2024, Kevin O'Byrne will succeed Scott and will be appointed as Chair of the Company.

Kevin has served as a Non-Executive Director of the Company since May 2019 and is currently the Company's Senior Independent Director and a member of the Nominations Committee and Audit and Risk Committee. Kevin was Chair of Centrica plc's Audit and Risk Committee from 2019 to 2023.

In line with UK Corporate Governance Code recommendations, as the Senior Independent Director was a candidate for the role of Chair, non-executive director Amber Rudd led a comprehensive search process, considering both internal and external candidates. 

Chris O'Shea, Group Chief Executive said: "On behalf of the Board I would like to thank Scott for the contribution he has made to Centrica, chairing the Board through a period of significant volatility and change for the Company. On a personal level, Scott has been a huge support to me and I have learned a lot from working with him. Centrica is a very different company to the one Scott asked me to lead in early 2020, and Scott leaves with the business in a great position.

I am grateful to Amber for running such a thorough and comprehensive process and I'm delighted Kevin has agreed to become our next chair. I'm looking forward to working with Kevin and the Board to drive further growth as we work to capture the opportunities our uniquely integrated business model creates for us."

Kevin O'Byrne, Senior Independent Director and Chair Designate said: "I am honoured and excited to take on the role of Chair at Centrica. I look forward to building on the strong foundations Scott has laid over his time as Chair, and to working with the Board, Chris and the executive team to execute the Company's strategy and deliver material value for all our stakeholders".

ENDS

Notes:

There are no other matters that require disclosure under rule 9.6.11R or 9.6.14R of the UK Listing Rules.

The Board has confirmed that Kevin O'Byrne is independent upon appointment.

Kevin O'Byrne will receive an annual fee of £440,000. Kevin will not be eligible to receive any pension or cash in lieu of pension allowance or participate in any discretionary compensation plans or long-term incentive plan.

Note to editors:

Kevin brings extensive executive and Board experience, in addition to knowledge of Centrica's operations, to the role. He has significant experience of complex financial and capital allocation decision making matters. Kevin has held CFO and CEO roles in a number of leading UK and international retailers since 2004, including Chief Financial Officer of J Sainsbury plc from 2017 to 2023. He was previously an executive director of Kingfisher plc and Dixons Retail plc. He was a non-executive director of Land Securities plc from 2008 to 2017 where he was Chair of the Audit Committee and Senior Independent Director. Kevin is currently also a non-executive director of NYSE listed International Flavors & Fragrances Inc (IFF), a multinational market leading supplier to the food, beverage, beauty, and household and personal care sectors. At IFF he is Chair of the Governance & Corporate Responsibility Committee and sits on the Innovation and Audit Committees.

Enquiries:

Investors and Analysts:

tel: +44 (0)1753 494900 

email: ir@centrica.com

 

Media:

tel: +44 (0)1784 843000

email: media@centrica.com

 

Centrica plc is listed on the London Stock Exchange (CNA)Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD

Registered in England & Wales number: 3033654Legal Entity Identifier number: E26EDV109X6EEPBKVH76ISIN number: GB00B033F229

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEADXLALELEAA
Date   Source Headline
1st Jun 20263:45 pmRNSTotal Voting Rights
26th May 202612:30 pmRNSDirector/PDMR Shareholding
22nd May 20262:00 pmRNSDirector/PDMR Shareholding
18th May 20264:00 pmRNSDirector/PDMR Shareholding
15th May 20267:00 amRNSBritish Gas agrees PPM settlement
14th May 20264:42 pmRNSPublication of a Prospectus
12th May 20263:15 pmRNSDirector/PDMR Shareholding
12th May 202612:15 pmRNSDirector/PDMR Shareholding
12th May 20267:10 amRNSDirectorate change
7th May 202612:15 pmRNSResult of AGM
7th May 20267:00 amRNSAcquisition of the Severn CCGT for c.£370 million
7th May 20267:00 amRNSAGM Statement
1st May 20262:30 pmRNSTotal Voting Rights
27th Apr 20262:30 pmRNSDirector/PDMR Shareholding
13th Apr 20263:30 pmRNSDirector/PDMR Shareholding
1st Apr 202612:00 pmRNSTotal Voting Rights
31st Mar 202610:33 amRNSNotice of AGM
25th Mar 20262:00 pmRNSDirector/PDMR Shareholding
11th Mar 20266:15 pmRNSDirector/PDMR Shareholding
2nd Mar 202612:15 pmRNSTotal Voting Rights
25th Feb 20265:15 pmRNSDirector/PDMR Shareholding
19th Feb 20262:39 pmRNSAnnual Financial Report 2025
19th Feb 20267:10 amRNSDirectorate change
19th Feb 20267:00 amRNSPreliminary Results
11th Feb 20265:30 pmRNSDirector/PDMR Shareholding
9th Feb 20267:00 amRNSCentrica announces divestments
2nd Feb 20263:00 pmRNSTotal Voting Rights
26th Jan 20264:15 pmRNSDirector/PDMR Shareholding
13th Jan 20263:00 pmRNSDirector/PDMR Shareholding
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20263:09 pmRNSTransaction in Own Shares - Replacement
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20267:00 amRNSTransaction in Own Shares
5th Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 202612:30 pmRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20267:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
29th Dec 20254:30 pmRNSCancellation of treasury shares
29th Dec 20254:30 pmRNSCancellation of treasury shares
29th Dec 20251:15 pmRNSDirector/PDMR Shareholding
29th Dec 20251:15 pmRNSDirector/PDMR Shareholding
29th Dec 20257:00 amRNSTransaction in Own Shares
29th Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.